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doi:10.1016/j.jmii.2011.12.015Background: Clinical information about non-typhoidal Salmonella (NTS) bacteremia in patients
with malignancy has rarely been described. This study investigated clinical characteristics and
prognostic variables of patients with malignancy while complicated with NTS bacteremia.
Methods: The study included demographic data, clinical information, and outcome in adults
(18 years old) with and without malignancy complicated with NTS bacteremia at a medical
center from 2000 to 2009.
Results: There were 206 patients with NTS bacteremia. The serogroups of NTS isolates
included group B (40.2%), group D (30.9%), group C (26.5%), and group E (1.5%). Extraintestinal
infections were noted in 66 (32.4%) patients and were mainly endovascular (26/206, 12.7%) or
pleuropulmonary (17/206, 8.3%) infections. On multivariate analysis, independent factors for
in-hospital mortality included shock (odds ratio [OR] 9.13; 95% confidence interval [CI] 3.81
e21.83; p < 0.001), malignancy (OR 8.42; 95% CI 3.12e22.71; p < 0.001), and acute renal
failure (OR 2.63; 95% CI 1.11e6.22; p Z 0.028). Different clinical presentations and outcome
were noted in 74 (36.2%) patients with malignancy and 130 without malignancy. The former
had more leucopenia and thrombocytopenia at initial presentation and fewer extraintestinal
infections (20.2% vs. 39.2%, p Z 0.005), endovascular infections (2.7% vs. 18.5%;
p Z 0.002), and serovar Choleraesuis (10.8% vs. 27.7%; p Z 0.005). An elevated in-hospital
mortality rate was noted in patients with malignancy compared to those without malignancy
(40.5% vs. 17.7%, p < 0.001). Among patients with malignancy, multivariate analysis revealed
that shock was the only independent factor associated with in-hospital mortality (OR 7.52; 95%
CI, 2.38e23.80; p Z 0.001).of Internal Medicine, National Cheng Kung University Hospital, No. 138, Sheng Li Road, Tainan 704,
u.edu.tw (W.-C. Ko).
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344 C.-W. Li et al.Conclusion: Malignancy is an adverse prognostic factor in patients with NTS bacteremia. Food
safety in patients with malignancy should be emphasized to prevent salmonellosis.
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Non-typhoidal Salmonella (NTS) is one of the important
causes of foodborne infections, resulting in self-limited
gastroenteritis, bacteremia, subsequent focal infection, or
persistence in endovascular sites.1 Several extraintestinal
infections, including endovascular infections, meningitis,
pneumonia, septic arthritis, or osteomyelitis were reported
as primary infectious foci or as secondary infections to
primary bacteremia.1,2 Aside from an elevated incidence of
extraintestinal organ involvement, an increased mortality
of patients with NTS bacteremia was also reported. NTS
bacteremia in children rarely causes fatalities, whereas NTS
bacteremia in adults should be considered life-threatening,
regardless of primary or secondary bacteremia.3,4 Mean-
while, NTS bacteremia possesses important clinical signifi-
cance because affected patients usually have underlying
diseases, suggesting an immunocompromised status.5e7
Previous studies have pointed out several conditions asso-
ciated with salmonellosis, including connective tissue
diseases, use of therapeutic immunosuppressants, malig-
nancies, diabetes mellitus, and human immunodeficiency
virus (HIV) infection.1,8e10
As mentioned in previous studies, malignancy and HIV
infection have been the leading predisposing medical
diseases in patients with NTS bacteremia,8,11 A study in
Spain reported up to 50% mortality among patients with HIV
infection complicated with non-typhoidal salmonellosis.12
In a previous Taiwanese study, solid-organ malignancy,
age, and extraintestinal infection were reported as inde-
pendent predictors for in-hospital death among patients
with NTS bacteremia.13 However, few reports investigated
the clinical characteristics and outcome for patients with
NTS bacteremia and underlying malignant diseases. This
study described the clinical characteristics and prognostic
variables at discharge among patients with malignancy and
NTS bacteremia.
Materials and methods
Study design
A retrospective study was conducted in a university-
affiliated hospital, which is a medical centre with 1,100
beds. Patients aged 18 or older with at least one blood
sample positive for NTS species identified by the clinical
microbiology laboratory between January 2000 and
December 2009 were included. Medical records regarding
demographic data, underlying diseases, clinical manifes-
tations, laboratory data upon admission, antimicrobial
treatment, clinical outcome and length of hospital stay
were reviewed. For patients with recurrent NTS bacter-
emia, only the first episode was included.Microbiology and antimicrobial susceptibility
All blood isolates were cultured and identified according to
standard methods.14 The serogroups of Salmonella isolates
were determined by O antisera (Difco Laboratories,
Detroit, MI, USA) first by the slide agglutination test. For
serogroup C or D isolates, the presence of Vi antigen in
Salmonella Typhi or Salmonella Paratyphi was screened by
Vi antisera (BBL, Cockeysville, MD, USA). Salmonella
enterica serotype Choleraesuis was identified if the citrate
test was negative in isolates of serogroup C1.15
Antimicrobial susceptibilities were determined using the
disk-diffusion method. The interpretation of susceptibility
data followed the criteria proposed by the Clinical Labo-
ratory Standard Institute.16
Definition
The infectious focus of bacteremia was determined clini-
cally by the presence of an active infection site concomi-
tant with NTS bacteremia, or the isolation of an identical
organism from clinical specimens other than blood and
feces. Patients were considered to have primary bacter-
emia if there was no clinical evidence of other infectious
focuses as well as no identical organism isolated from
a clinical specimen other than blood and feces.
Patients were assumed to have diabetes mellitus if the
fasting serum glucose level was>126 mg/dL. Chronic kidney
disease was defined as a serum creatinine >1.5 mg/dL.
Liver cirrhosis was defined by abdominal ultrasonography
and findings from clinical follow-up. Immunosuppressive
therapy was defined as the receipt of corticosteroid (at
least 10 mg of prednisolone per day or equivalent dosage for
at least two weeks), anti-neoplastic treatment for malig-
nancy, or immunosuppressive agents for organ trans-
plantation within one month prior to admission.
Fever was defined as an axillary body temperature
38C. Shock was defined as a systolic blood pressure
90 mmHg or an unstable hemodynamic status requiring
inotropic agents to maintain blood pressure. Acute renal
failure was defined as a 2-fold increase of the patient’s
baseline creatinine level. Antimicrobial therapy was
considered appropriate if the etiological pathogen was
susceptible in vitro to at least one of the drugs adminis-
tered within 72 hours after the onset of bacteremia.
Statistical analysis
Data analysis was conducted using the Statistical Package
for the Social Sciences (SPSS) for Windows (Version 17.0;
SPSS, Chicago, IL, USA). Continuous variables were
expressed as mean  standard deviation and were
compared using the Student’s t test. Categorical variables,
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using the chi-squared test or Fisher’s exact test. The odds
ratio (OR) and corresponding 95% confidence interval (CI)
for mortality were calculated in the unadjusted and
multivariable-adjusted models. Multivariate analysis was
performed with the stepwise logistic regression model on
the variables with a p value 0.1 as the limit for entering
the variable. A Cox proportional hazard model was used to
compare the survival in malignancy and non-malignancy
groups and was adjusted for age, gender, shock, and
acute renal failure.
Results
During the 10-year period, a total of 206 patients with NTS
bacteremia were evaluated. Two patients were excluded
for analysis due to a loss of medical information from
transference to other hospitals. Of 204 patients with NTS
bacteremia, 74 (36.2%) had underlying medical illnesses of
solid organ malignancy or hematological malignancy.
Overall, 53 patients died in the hospital, attributing to an
in-hospital mortality rate of 26.0% in patients with NTS
bacteremia.
Clinical characteristics and laboratory data
The demographic data of 204 patients are described in
Table 1. Of the 204 patients with NTS bacteremia, the mean
( standard deviation) age was 58.4 (18.3) years with
a range of 19e98 years and males predominating (121/204,
59.3%). At least one underlying medical disease was noted in
177 (86.8%) patients. 74 patients had malignant diseases,
and 47 had a solid organ tumor, mainly hepatocellular
carcinoma (14), gastrointestinal cancer (10), or lung cancer
(8). The other 27 patients had hematological malignancies
with a predominance of lymphoma (8) and acute leukemia
(7). Only 2 patients had cured malignant diseases and 27
(40%) patients received anti-neoplastic treatment within
one month prior to onset of NTS bacteremia. Of 77 patients
tested for HIV infection, 13 (6.4%) were positive for HIV-1
antibody and the CD4 counts at presentation were  40
cells/mm3. As a result, all 13 patients were regarded as
cases of acquired immunodeficiency syndrome (AIDS). Only
one patient had concurrent HIV infection and multiple
myeloma. The distribution of serogroups of NTS isolates was
in the order of group B (40.2%), group D (30.9%), group C
(26.5%), and group E (1.5%). Meanwhile, themajority (81.5%)
of serogroup C isolates belonged to serovar Choleraesuis.
Up to 73.5% of patients presented with fever at admis-
sion and only 12.2% had gastroenteritis symptoms. About
one-fourth (27%) of patients experienced a shock episode
and 31.4% had acute renal failure at the onset of NTS
bacteremic events. Generally, primary bacteremia without
obvious infectious focus was reported, accounting for
67.6% of patients. Among those with extraintestinal focal
infections, 26 (39.4%) patients had invasive endovascular
infections as the most common extraintestinal infection
followed by pleuropulmonary infections (17, 25.8%) and
spinal osteomyelitis (6, 9.1%).
In the present study, 144 (70.6%) of 204 patients have
been empirically treated by appropriate antimicrobialagents, such as third-generation cephalosporins, fourth-
generation cephalosporins, or fluoroquinolones, according
to the in vitro susceptibility data.
Mortality among patients with NTS bacteremia
Overall, 53 (26.0%) patients died during hospitalization and
27 (13.2%) could not survive for 14 days. Univariate analysis
showed that several variables associated with in-hospital
mortality included old age (p Z 0.007), congestive heart
failure (pZ 0.003), connective tissue diseases (pZ 0.022),
malignancy (p < 0.001), absence of fever (p Z 0.001),
gastroenteritis symptoms (p Z 0.001), shock (p < 0.001),
leukocytosis (p Z 0.036), thrombocytopenia (p Z 0.004),
acute renal failure (p < 0.001), and presence of extra-
intestinal infections (p < 0.001), as shown in Table 2.
However, multivariate logistic regression analysis revealed
that only shock (adjusted odds ratio [aOR] 9.13; 95% CI
3.81e21.83; p < 0.001), malignancy (aOR 8.42; 95% CI
3.12e22.71; p < 0.001), and acute renal failure (aOR 2.63;
95% CI 1.11e6.22; p Z 0.028), were independently associ-
ated with in-hospital mortality. As for clinical manifesta-
tions, mycotic aneurysm, the most common extraintestinal
infection, has shown a borderline significance (p Z 0.080)
in association with in-hospital mortality rates (Table 3).
Differences of clinical characteristics between NTS
bacteremic patients with and without malignancy
The comparison of clinical characteristics between patients
with malignancy and without malignancy is shown in
Table 1. Patients with malignancy were less likely to have
hypertension (p Z 0.001), connective tissue disease
(p < 0.001), and HIV infection (pZ 0.034), but more likely
to have liver cirrhosis (p Z 0.023). Concerning initial clin-
ical presentations, leukopenia and thrombocytopenia were
present more often in patients with malignancy (pZ 0.009
and 0.034, respectively). However, patients with malig-
nancy had less extraintestinal infections (p Z 0.005),
including invasive endovascular infections (p Z 0.002),
serogroup C bacteremia (pZ 0.013), and especially serovar
Choleraesuis (p Z 0.005).
Mortality among patients with malignancy and NTS
bacteremia
An elevated in-hospital mortality rate was noted in patients
with malignancy compared to 130 patients without malig-
nancy, (40.5%, 30/ 74 vs. 17.7%, 23/130; p < 0.001). The
Cox proportional hazard model was applied after adjusting
for confounding variables of age, gender, shock, and acute
renal failure. The survival rate of patients with NTS
bacteremia and malignancy compared to those without
malignancy was significantly different (p Z 0.02), with
a relative hazard of death of 2.08 (95% CI, 1.11e3.88)
(Fig. 1).
Absence of fever (p Z 0.024) or shock (p < 0.001) and
the presence of extra-intestinal infections (p Z 0.021)
were significant risk factors associated with unfavorable
outcomes in patients with malignancy complicated with
NTS bacteremia in the univariate analysis. Active status of
Table 1 Demographic data and clinical characteristics of 204 patients with non-typhoidal salmonella bacteremia and
comparisons between patients with malignancy and without malignancy
Characteristics No. of
patients (%)
No. of patient (%) P
valueMalignancy (n Z 74) No-malignancy (n Z 130)
Age, mean (standard deviation; range), y 58.4 (18.34;19e98) 61.1 (14.9; 20e90) 56.9 (19.9;19e98) 0.116
Male gender 121 (59.3) 46 (63.0) 75 (57.7) 0.556
Underlying diseases
Immunosuppressive therapy 72 (35.3) 31 (41.9) 41 (31.5) 0.170
Hypertension 69 (33.8) 14 (18.9) 55 (42.3) 0.001
Diabetes mellitus 61 (29.9) 19 (25.7) 42 (32.3) 0.344
Chronic kidney diseases 60 (29.4) 16 (21.6) 44 (33.8) 0.079
Connective tissue diseases 37 (18.1) 2 (2.7) 35 (26.9) <0.001
Liver cirrhosis 24 (11.8) 14 (18.9) 10 (7.7) 0.023
Congestive heart failure 22 (10.8) 4 (5.4) 18 (13.8) 0.098
Chronic lung diseases 20 (9.8) 4 (5.4) 16 (12.3) 0.143
Coronary artery diseases 20 (9.8) 5 (6.7) 15 (11.5) 0.333
Human immunodeficiency virus infection 13 (6.4) 1 (1.4) 12 (9.2) 0.034
Clinical presentations at bacteremic onset
Fever 150 (73.5) 49 (66.2) 101 (77.7) 0.066
Gastroenteritis symptoms 25 (12.2) 6 (8.1) 19 (14.6) 0.191
Shock 55 (27.0) 23 (31.1) 32 (24.6) 0.329
Leukocytosis 89 (43.6) 30 (40.5) 59 (45.4) 0.558
Leukopenia 30 (14.7) 18 (24.3) 12 (9.2) 0.009
Thrombocytopenia 56 (27.5) 27 (36.5) 29 (22.3) 0.034
Acute renal failure 64 (31.4) 22 (29.7) 42 (32.3) 0.755
Extra-intestinal infections
Primary bacteremia 138 (67.6) 59 (79.7) 79 (60.8) 0.005
Secondary bacteremia 66 (32.4) 15 (20.2) 51 (39.2) 0.005
Mycotic aneurysm/infective endocarditis 26 (12.7) 2 (2.7) 24 (18.5) 0.002
Pleuropulmonary infections 17 (8.3) 5 (6.8) 12 (9.2) 0.539
Spinal osteomyelitis 6 (2.9) 0 (0.0) 6 (4.6) 0.089
Others 17 (8.3)* 8 (10.8) 9 (6.9) 0.430
Serogroups of Salmonella species
group B 82 (40.2) 36 (48.6) 46 (35.4) 0.075
group C 54 (26.5) 12 (16.2) 42 (32.3) 0.013
Choleraesuis 42 (20.6) 8 (10.8) 36 (27.7) 0.005
group D 63 (30.9) 25 (33.8) 38 (29.2) 0.531
group E 3 (1.5) 0 (0.0) 3 (2.3) 0.555
unspecified 2 (1.0) 1 (1.4) 1 (0.8) 1.000
Appropriate antimicrobial therapy within 72 h 144 (70.6) 47 (63.5) 97 (74.6) 0.109
In-hospital mortality 53 (26.0) 30 (40.5) 23 (17.7) <0.001
* Others included liver/spleen abscess (5 cases), spontaneous bacterial peritonitis (3 cases), septic arthritis (3 cases), catheter-related
bloodstream infections (2 cases), cellulitis (2 cases), biliary tract infection (1 case) and anal fistula (1 case).
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or anti-neoplastic treatment one month prior to the
bacteremic episode, was not related to in-hospital
mortality for this patient group. Multivariate logistic
regression analysis revealed shock as the only independent
factor associated with in-hospital mortality (aOR 7.52; 95%
CI, 2.38e23.80; p Z 0.001).Discussion
Malignancy is a common underlying medical condition in
patients with NTS bacteremia in previous reports4,6,8 and in
our study. Prior to this study, the association of malignancyand mortality in patients with NTS bacteremia was rarely
described. On the basis of univariate analysis, a higher
mortality rate was seen in patients with underlying
congestive heart failure and malignancy, especially with
solid organ tumor(s). Multivariate analysis revealed that
only malignancy is a significant predictor for in-hospital
mortality. In our study, patients with malignancy had
a worse prognosis than those without malignancy (40.5% vs.
17.7%, p < 0.001).
The leading pathogens for bacteremia were Escherichia
coli, followed by Klebsiella pneumoniae and Pseudomonas
species,17e20 while Salmonella bacteremia remained a low
incidence.21 Whether underlying malignancy adversely
affects the clinical outcome of patients with bacteremia
Table 2 Univariable analysis of risk factors of mortality among patients with non-typhoidal Salmonella bacteremia
Characteristics No. of patient (%) Odds
ratio
95% confidence
interval
P
valueFatal (n Z 53) Surviving (n Z 151)
Age, mean (standard deviation; range), y 64.2 (15.3; 19-98) 56.4 (18.9; 19-98) 0.007
Male gender 32 (60.4) 89 (58.9) 1.06 0.56e2.01 0.873
Comorbidities
Immunosuppressive therapy 20 (37.7) 52 (34.4) 1.12 0.60e2.21 0.739
Diabetes mellitus 14 (26.4) 47 (51.1) 0.79 0.39e1.60 0.602
Chronic kidney diseases 17 (32.1) 43 (28.5) 1.19 0.60e2.33 0.605
Hypertension 18 (34.0) 51 (33.8) 1.01 0.52e1.95 1.000
Liver cirrhosis 10 (18.9) 14 (9.3) 2.28 0.94e5.49 0.082
Coronary artery diseases 8 (15.1) 12 (7.9) 2.06 0.79e5.36 0.177
Congestive heart failure 12 (22.6) 10 (6.6) 4.13 1.66e10.24 0.003
Chronic lung diseases 5 (9.4) 15 (9.9) 0.94 0.33e2.74 1.000
Connective tissue diseases 4 (7.5) 33 (21.9) 0.29 0.10e0.87 0.022
Human immunodeficiency virus infection 2 (3.8) 11 (7.3) 0.50 0.11e2.33 0.521
Malignancy 30 (56.6) 44 (29.1) 3.18 1.66e6.06 <0.001
Solid organ tumor 20 (37.7) 28 (18.5) 2.66 1.34e5.31 0.008
Hematological malignancy 10 (18.9) 16 (10.6) 1.72 0.74e4.00 0.246
Clinical presentations at bacteremic onset
Fever 30 (56.6) 120 (79.5) 0.32 0.16e0.62 0.001
Gastroenteritis symptoms 27 (50.9) 38 (25.2) 3.09 1.61e5.93 0.001
Shock 35 (66.0) 20 (13.2) 12.74 6.09e26.64 <0.001
Leukocytosis 30 (56.6) 59 (39.1) 2.03 1.08e3.83 0.036
Leukopenia 10 (18.9) 20 (13.2) 1.52 0.66e3.51 0.368
Thrombocytopenia 23 (43.3) 33 (21.9) 2.74 1.41e5.34 0.004
Acute renal failure 30 (56.6) 34 (22.5) 4.49 2.31e8.72 <0.001
Extra-intestinal infections 28 (52.8) 38 (25.2) 3.33 1.73e6.40 <0.001
Mycotic aneurysm 13 (24.5) 12 (7.9) 3.77 1.59e8.90 0.003
Pleuropulmonary infections 5 (9.4) 12 (7.9) 1.21 0.40e3.6 0.774
Serogroups
group B 23 (43.3) 59 (39.1) 1.20 0.63e2.25 0.627
group C 15 (28.3) 39 (25.8) 1.13 0.56e2.28 0.721
Choleraesuis 12 (22.6) 32 (21.1) 1.09 0.51e2.31 0.847
group D 15 (28.3) 48 (31.8) 0.85 0.43e1.69 0.731
group E 0 (0.0) 3 (2.0) 0.74 0.68e0.80 0.569
unspecified 0 (0.0) 2 (1.3) 0.73 0.68e0.80 1.000
Appropriate antimicrobial therapy within 72 h 40 (75.4) 104 (68.9) 1.47 0.71e3.07 0.374
Table 3 Multivariable analysis of factors associated with
in-hospital mortality determined by stepwise logistic
regression analyses
Variables Adjusted
odds ratioa
95%
confidence
interval
P
value
Shock 9.13 3.81e21.83 <0.001
Malignancy 8.42 3.12e22.71 <0.001
Mycotic aneurysm 3.30 0.87e12.53 0.080
Acute renal failure 2.63 1.11e6.22 0.028
Extraintestinal infections 2.51 0.89e7.08 0.083
a Adjusted variables include underlying liver cirrhosis,
congestive heart failure, connective tissue disease, the pres-
ence of fever, gastrointestinal symptoms, leukocytosis, and
thrombocytopenia.
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malignancy served as an independent variable for
mortality.22 Conversely, some studies failed to identify
malignancy as an independent risk factor for mortality in
patients with K pneumoniae23 or Pseudomonas aeruginosa20
bacteremia. In the present study, malignancy was signifi-
cantly associated with mortality in patients with NTS
bacteremia. Such an unfavorable outcome might be multi-
factorial and difficult to define in the present study of
retrospective characteristics but could potentially be
related to underlying malignant diseases, anti-neoplastic
treatment, or NTS septicemia itself.
The prevalence of NTS species varies in different areas.
In a study conducted in Malaysia, which included 55 cases of
NTS bacteremia, serogroup D was most common and
demonstrated the highest blood invasiveness.8 A study in
Taiwan demonstrated a high prevalence of serogroups B
and C17 while another study in Thailand reported
Figure 1. Survival curves of patients with non-typhoidal
Salmonella bacteremia with and without malignancy, adjusted
for age, gender, shock, and acute renal failure in the Coxmodel.
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patients.11,24 We found peculiar trends in serogroups in
the 10-year period of this study. Decreasing proportions
of Salmonella Choleraesuis and increasing proportions of
Salmonella serogroup D could be detected. S Choleraesuis
was less frequently found in patients with malignancy
than in patients without malignancy (10.8% vs. 27.7%,
p Z 0.005). S Choleraesuis has been reported to cause
invasive extraintestinal infections in humans.25,26 Patients
with solid-organ tumor(s) are considered less likely to
develop endovascular infections,13 as noted in the present
study. In addition to a possible explanation that patients
with malignancy are regularly cared for in hospitals and
more likely to seek medical advice if feeling sick, fewer S
Choleraesuis infections may contribute to a reduced
number of endovascular infections.
Previous reports have demonstrated that S Choleraesuis
was more resistant to certain antimicrobial agents than
serogroup B or D isolates in Taiwan.6,27 Up to 70% of S
Choleraesuis isolates were resistant to fluoroquinolones.15
Thus, fluoroquinolones might not be used empirically for
invasive salmonellosis in Taiwan unless these drugs can be
proven to be in vitro active against the causative Salmo-
nella isolates. A multistate study conducted in the United
States from 1996e2007 reported that 2.5% of invasive S
enterica isolates were resistant to ceftriaxone.28 On the
other hand, cefepime and carbapenem remain active
among non-typhoid Salmonella isolates from Taiwan.6
Therefore, appropriate antimicrobial agents should be
prescribed according to local susceptibility data for severe
NTS infections, such as invasive endovascular infections.
NTS Salmonella infections in healthy younger adults
might be self-limited without requiring routine antimicro-
bial treatment. However, among patients with an immu-
nocompromised condition such as malignancy, Salmonella
infections could be fatal, as compared with immunocom-
petent patients. Since the acquisition of Salmonella species
is mainly from contaminated food products associated
with certain animals (e.g., chicken and pigs), healthcare
providers should advise patients with malignancy not to eatraw or undercooked eggs, meat, poultry, and unpasteurized
dairy products. Once the diagnosis of Salmonella bacter-
emia is suspected or confirmed, aggressive antimicrobial
treatment should be undertaken, especially in patients
with malignancy.
Our study had some limitations. Because this study was
retrospective and with limited information obtained from
medical records, the mortality directly related to sepsis
was difficult define. In addition, antimicrobial minimal
inhibitory concentration (MIC) studies or serovars of
bacteremic NTS isolates were not routinely performed.
However, in vitro disk diffusion tests following the recom-
mendations of Clinical Laboratory Standard Institute (CLSI)
were completed. Finally, the extent of immunocomprom-
isation posed by underlying malignancy was heterogeneous
and not able to be qualified for various types of malignancy.
Thus, underlying malignancy for each patient may
contribute variably to the clinical outcome.
In conclusion, malignancy is a variable associated with
an unfavorable outcome in patients with NTS bacteremia.
Therefore, patients with malignancy and with suspected or
documented NTS bacteremia should receive antimicrobial
treatment as soon as possible. Also, food hygiene is critical
for preventing severe NTS infections in immunocompro-
mised patients.References
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